

## **SPCC** Project Proposal

# Cancer & Covid: Prevention and Treatment including Monoclonal Antibodies (MoABs)

## 2022/2023



### **PROJECT OUTCOMES**

#### FIRST STEP - TASK FORCE: 22 June 2022

A virtual task force to discuss new strategies to tackle cancer and covid using all approved agents and monoclonal antibodies (MoAB) in prevention and treatment.

## SECOND STEP - SCIENTIFIC POSITION STATEMENT

Dr. Adriana Albini - Editor-in-Chief of <u>Cancerworld</u> (medical magazine funded and distributed by SPCC) attended the Task Force as observer and produced a report. To read the full article please <u>click here</u>.

#### **THIRD STEP - WEBINARS**

**Format:** 3 live webinars via <u>www.oncocorner.net</u> Each live session will be recorded and, after one week, made available on-demand on the SPCC OncoCorner platform.

#### Webinar duration: 60 minutes each

#### **Tentative Timeline**

Webinar 1 – January 2023 Webinar 2 – March 2023 Webinar 3 – March 2023

#### Outcomes

A series of reports (3) summarising the highlights of each webinar and panel discussion will be published on the <u>Cancerworld website</u>.

A scientific journalist will produce these reports, for which the collaboration of all faculty will be required. Before publication, each report will have to be evaluated and approved by all faculty of the webinar.



## SUGGESTED WEBINAR PROGRAMME

Webinar 2 - March 2023Date: Wednesday 8 March 2023Time: from 18:00 to 19:00 CET (with connection at 17:40 CET for technical briefing)

Webinar Title: "Treatment of COVID complications"

## Webinar Experts

Alfredo Addeo, CH - Marco Cavaleri, NL - Justing Stebbing, UK

## Webinar Chair/Discussant

Giovanni Di Perri, IT

### **Draft Webinar Programme**

18:00 CET Introduction - Giovanni Di Perri, IT		
18:05 CET COVID and lung cancer patients: focus on the effe	COVID and lung cancer patients: focus on the effects of treatment - Alfredo Addeo, CH	
18:15 CET Drugs approved by EMA: indications and limitatio	Drugs approved by EMA: indications and limitations - Marco Cavaleri, NL	
18:25 CET From AI to regulatory approval in 9 months: the	e pandemic baricitinib story ·	Justing
Stebbing, UK		
18:35 CET Discussion and Q&A - Chair and Experts		
18:55 CET Take Home Messages and Closure - Giovanni Di P	Perri, IT	